Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.
Swiss pharmaceutical giant Roche has signed an exclusive licensing and collaboration agreement with Nurix Therapeutics for bexobrutinib, a protein degrader drug targeting B cell malignancies and blood cancers. The deal value is reported as up to $2.3 billion by one source and up to $3 billion by another.
Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.
The FDA is reviewing a petition to revoke approval of ocrelizumab (Ocrevus), Roche's top-selling drug, for treating primary progressive MS, raising questions about whether the drug may be causing more harm than good in this patient population.
